Patents Assigned to Zeneca
  • Patent number: 8466284
    Abstract: The invention provides certain novel compounds as listed in the specification and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 18, 2013
    Assignee: Astra Zeneca AB
    Inventors: David Chapman, Martin Lindsjö, Hans Lönn, Michael Lundkvist, Magnus Munck AF Rosenschöld, Antonios Nikitidis, Debra Ainge, John Pavey
  • Publication number: 20100041912
    Abstract: A process for the preparation of carboprost methyl ester (FIG. (10)).
    Type: Application
    Filed: January 5, 2007
    Publication date: February 18, 2010
    Applicant: Astra Zeneca
    Inventors: Keshav Shripad Bhide, Govindrao Abhijit Padhye, Madhukar Niranjan Paingankar
  • Publication number: 20080188518
    Abstract: Compounds of formula I: wherein A and R1 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Application
    Filed: November 15, 2004
    Publication date: August 7, 2008
    Applicant: ASTRA ZENECA AB
    Inventors: James Empfield, Eifion Phillips, Scott Throner
  • Publication number: 20070135455
    Abstract: A compound of the formula(I); wherein the substituents are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man. The compounds are inhibitors Tie2 receptor tyrosine kinase (TEK).
    Type: Application
    Filed: February 1, 2005
    Publication date: June 14, 2007
    Applicant: Astra Zeneca AB
    Inventors: Clifford Jones, Richard Luke, William McCoull
  • Publication number: 20070099957
    Abstract: Compounds of formula: (I) wherein R1, R2, R3, R4 and R7 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: May 13, 2004
    Publication date: May 3, 2007
    Applicant: Astra Zeneca AB
    Inventors: William Brown, Andrew Griffin, Shujuan Jin
  • Patent number: 7173025
    Abstract: Compounds of formula (I), wherein G1 is CH or N; G2 is CH or N; R1 is a variety of optional substituents; L1 is (1-4C)alkylene; T1 is CH or N; R2 and R3 are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X1 and X2 represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: February 6, 2007
    Assignee: Zeneca Limited
    Inventors: Andrew Stocker, John Preston, Michael James Smithers
  • Publication number: 20060116389
    Abstract: A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I) wherein C is selected from D and E, formula (II) R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected from for example H, F, CF3, Me and Et; R1b is —NRz-Z wherein Rz is for example hydrogen and Z is a 5- or 6-membered heteroaryl ring; R4 is for example an optionally substituted 5- or 6-membered heterocyclic ring system. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.
    Type: Application
    Filed: December 15, 2003
    Publication date: June 1, 2006
    Applicant: ASTRA ZENECA AB
    Inventors: Michael Gravestock, Neil Hales, Paul Turner
  • Patent number: 6953809
    Abstract: The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: October 11, 2005
    Assignee: Zeneca Limited
    Inventors: Alan Wellington Faull, Andrew John Barker, Jason Grant Kettle
  • Patent number: 6946468
    Abstract: The present invention relates to inhibitors of ras farnesylation of the Formula I wherein: R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CH2—NH— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms where the heteroatoms are independently selected from O, N & S; or a —S—S— dimer thereof when R2?H; or a N-oxide or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation their use as therapeutic agents and pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: September 20, 2005
    Assignee: Zeneca Limited
    Inventors: Francis Thomas Boyle, James Michael Wardleworth
  • Patent number: 6911458
    Abstract: The invention provides compounds of general formula (I) wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: June 28, 2005
    Assignee: Astra Zeneca
    Inventors: Tomas Eriksson, Tomas Klingstedt, Tesfaledet Mussie
  • Patent number: 6897214
    Abstract: The invention concerns quinazoline derivatives of the formula I wherein X1 is a direct link or a group such as CO, C(R2)2 and CH(OR2); wherein Q1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: May 24, 2005
    Assignee: Zeneca Limited
    Inventors: Andrew John Barker, Craig Johnstone
  • Patent number: 6897210
    Abstract: The invention relates to quinazoline derivatives of formula (I) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: May 24, 2005
    Assignees: Zeneca Limited, Zeneca Pharma S. A.
    Inventors: Andrew Peter Thomas, Craig Johnstone, Edward Clayton, Elaine Sophie Elizabeth Stokes, Jean-Jacques Marcel Lohmann, Laurent Francois Andre Hennequin
  • Publication number: 20050107362
    Abstract: Heterocyclic amides of formula (1) wherein: is a single or double bond; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is —NR2R3 or —OR3; R2 and R3 are selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C1-4alkyl(optionally substituted by 1 or 2 R8 groups); R4 is selected from for example hydrogen, halo, nitro, cyano, hydroxy, C1-4alkyl, and C1-4alkanoyl; R8 is selected from for example hydroxy, —COCOOR9, —C(O)N(R9)(R9), —NHC(O)R9, (R9)(R10)N— and —COOR9; R9 and R10 are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13); R13 is selected from hydroxy, halo, trihalomethyl and C1-4alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity.
    Type: Application
    Filed: March 4, 2003
    Publication date: May 19, 2005
    Applicant: Astra Zeneca AB
    Inventors: Paul Robert Whittamore, Stuart Norman Bennett, Iain Simpson
  • Patent number: 6874928
    Abstract: Apparatus for mixing a number of components comprising a vessel for receiving the components, drive means for rotating or oscillating the vessel about an axis to effect mixing of the components within the vessel, and at least one spectroscopic monitoring means for repeatedly scanning the mixture to obtain data for use in monitoring changes in the spectroscopic profile of the mixture as mixing proceeds, the monitoring means by mounted off-axis relative to the axis about which the vessel is rotatable or oscillatable.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: April 5, 2005
    Assignee: Astra Zeneca U.K. Limited
    Inventors: Ali Mohammad Afnan, Robert Symes Chisholm
  • Patent number: 6846814
    Abstract: Compounds having the general formula wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z and n are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: January 25, 2005
    Assignee: Astra Zeneca AB
    Inventors: Jeffrey Scott Albert, Peter Bernstein, Cyrus Ohnmacht, Jr., Keith Russell, Ashokkumar Bhikkappa Shenvi
  • Publication number: 20040242574
    Abstract: The invention relates to quinazoline derivatives of formula (I) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl), R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro, X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or hetrocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain
    Type: Application
    Filed: November 3, 2003
    Publication date: December 2, 2004
    Applicants: ZENECA LIMITED, ZENECA PHARMA S.A.
    Inventors: Andrew Peter Thomas, Craig Johnstone, Edward Clayton, Elaine Sophie Elizabeth Stokes, Jean-Jacques Marcel Lohmann, Laurent Francois Andre Hennequin
  • Patent number: 6809097
    Abstract: Compounds of the formula (I): wherein: R2 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents —O—, —NH—, —S— or —CH2—; G1 represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y1, Y2, Y3 and Y4 each independently represents carbon or nitrogen; R1 represents fluoro or hydrogen; m is an integer from 1 to 3; R3 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR4R5 (wherein R4 and R5, can each be hydrogen or C1-3alkyl), or a group R6—X1— wherein X1 represents —CH2— or a heteroatom linker group and R6 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may hav
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: October 26, 2004
    Assignees: Zeneca Limited, Zeneca Pharma S.A.
    Inventors: Andrew Peter Thomas, Laurent Francois Andre Hennequin, Patrick Ple
  • Patent number: 6787562
    Abstract: Compounds of the formula I; useful for the treatment of pain wherein A, Z, B, R1, X and D are as defined in the specification, methods of making such compounds, methods of using such compounds and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: September 7, 2004
    Assignee: Zeneca Ltd.
    Inventors: Gloria Anne Breault, John Oldfield, Howard Tucker, Peter Warner
  • Patent number: 6767571
    Abstract: Flavoring materials may be produced from filamentous fungi by contacting them with water at a temperature sufficient to reduce their nucleic acid content and concentrating or separating solids from the resulting aqueous solution. The materials may be further subjected to a chemical reaction for example with a sulphur containing amino acid.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: July 27, 2004
    Assignee: Zeneca Limited
    Inventors: Graham Wood Rodger, Geoffrey Bryan Cordell, Donald Stewart Mottram
  • Patent number: RE38916
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: December 6, 2005
    Assignees: The Johns Hopkins University, The University of Utah, The Cancer Institute, Zeneca Limited
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuka Nakamura, Andrew Thilveris, Raymond L. White